Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688545 · ClinicalTrials.gov registry record
Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
A clinical trial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- 275
- Enrollment target
NCT00688545 is a clinical trial that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 275 participants.
The verdict
NCT00688545 was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- 275 participants
- Enrollment target
Study Summary
This multi-center observational Registry will collect long-term safety data on patients treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) as used in clinical practice for the treatment of Juvenile Idiopathic Arthritis (JIA).
Interventions
- DRUG Celecoxib
- DRUG nsNSAIDs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688545
The ClinicalTrials.gov registry entry for NCT00688545 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT00688545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688545 about?
NCT00688545 is a clinical study titled "Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis". This multi-center observational Registry will collect long-term safety data on patients treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) as used in clinical practice for the treatment of Juvenile Idiopathic Arthritis (JIA).
What is the current status of trial NCT00688545?
This trial is currently terminated. The enrollment target is 275 participants. The study started on 2009-04. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00688545?
The interventions under investigation include: Celecoxib (DRUG), nsNSAIDs (DRUG).
Who is sponsoring clinical trial NCT00688545?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.